awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q56897679
Q56897679
Item
http://www.wikidata.org/entity/Q56897679
Q56897679
about
Q56897552
P2860
Q56897552-2E5C3E5A-3D3B-4103-A07A-5906E51D763F
P2860
Q56897679
Item
http://www.wikidata.org/entity/Q56897679
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2012
@uk
type
Item
P1433
Q56897679-A37AE9F2-3E94-4900-A28D-B236060B74E9
P2093
Q56897679-5C7AE9E0-DAB6-4E61-916A-653E68867D37
Q56897679-7E868164-4740-4F26-AA76-0F2E94F60B2D
Q56897679-BCA77519-77B4-4DC6-9B55-3B966A9FFB34
P2860
Q56897679-0A1D6BF7-31D7-422D-8853-01412C744D55
Q56897679-46B7D6C5-801C-42B0-A492-E2CA768AF8C1
Q56897679-4EDDFC0C-3DB4-4B4F-8070-B705F13FFBFE
Q56897679-4FE7CAD9-6606-4790-83B8-457EDCB6818D
Q56897679-56D6E5DF-B59A-426E-A80C-B0ABF80E88EF
Q56897679-5BB5E66F-1963-41D3-B86D-ED2376E1A8FA
Q56897679-6BDD7A7B-34A7-4FCA-8C5E-0EAD4DC23DB1
Q56897679-6F09E54B-CE43-4F25-87A3-13EE8BA55035
Q56897679-734D1E83-BC47-4A38-8DA8-9EE36A51857C
Q56897679-7361CC01-0C4C-423F-9CE1-22DC74864600
Show more
P2888
Q56897679-137DD139-A694-4A3D-9E1C-DCD64F2183A7
P304
Q56897679-21ED2F95-8E7A-4179-A3F9-34579F83A794
P31
Q56897679-884297AA-70FF-44EF-9943-52AB77261060
P356
Q56897679-4C104F54-4F2C-4D81-A708-AD77B6011356
P433
Q56897679-37A43BDF-2F0F-446B-913D-61C4A14AA381
P478
Q56897679-ED3157DA-983B-4E29-96DB-497C0F0D0C29
P577
Q56897679-8DE98154-E89B-49EF-B099-7D6BDEDEAC12
P698
Q56897679-60644D16-AF76-400D-8202-22D1E93CB1D6
P356
S00105-012-2470-4
P1433
Hautarzt
P2093
D Schadendorf
http://www.w3.org/2001/XMLSchema#string
J Vaubel
http://www.w3.org/2001/XMLSchema#string
L Zimmer
http://www.w3.org/2001/XMLSchema#string
P2860
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
The B7 family revisited
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
Final version of 2009 AJCC melanoma staging and classification
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Show more
P2888
s00105-012-2470-4
P304
952-8
http://www.w3.org/2001/XMLSchema#string
P31
scholarly article
P356
10.1007/S00105-012-2470-4
http://www.w3.org/2001/XMLSchema#string
P433
12
http://www.w3.org/2001/XMLSchema#string
P478
63
http://www.w3.org/2001/XMLSchema#string
P577
2012-12-01T00:00:00Z
http://www.w3.org/2001/XMLSchema#dateTime
P698
23097082
http://www.w3.org/2001/XMLSchema#string